ProCE Banner Activity

BOSTON: Phase III Trial of Weekly Selinexor, Bortezomib, and Dexamethasone Vs Twice Weekly Bortezomib and Dexamethasone in Pretreated Patients With Multiple Myeloma

Slideset Download
Conference Coverage
Weekly triplet regimen SVd significantly improved PFS compared with twice weekly Vd in multiple myeloma patients with 1-3 previous therapies

Released: June 01, 2020

Expiration: May 31, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono